Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors.
about
Kinetic mRNA Profiling in a Rat Model of Left-Ventricular Hypertrophy Reveals Early Expression of Chemokines and Their ReceptorsCardiac sympatho-vagal balance and ventricular arrhythmiaSmooth muscle actin determines mechanical force-induced p38 activationThe influence of body mass index, age and sex on inflammatory disease risk in semi-captive ChimpanzeesCoronary artery remodeling in a model of left ventricular pressure overload is influenced by platelets and inflammatory cells.Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community.Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive ratsHigh-sodium intake aggravates myocardial injuries induced by aldosterone via oxidative stress in Sprague-Dawley rats.Selective gene expression analysis of muscular and vascular components in hearts using laser microdissection method.Role of endothelins in animal models of hypertension: focus on cardiovascular protection.Tumor necrosis factor: a mechanistic link between angiotensin-II-induced cardiac inflammation and fibrosis.High Sensitivity C - Reactive Protein is Associated with Diastolic Dysfunction in Young African Americans without Clinically Evident Cardiac DiseaseInhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload.The role of endothelin-1 in myocarditis and inflammatory cardiomyopathy: old lessons and new insights.Cardiac fibrosis in the elderly, normotensive athlete: case report and review of the literature.In vitro studies of early cardiac remodeling: impact on contraction and calcium handling.Cardiomyocyte-specific endothelin A receptor knockout mice have normal cardiac function and an unaltered hypertrophic response to angiotensin II and isoproterenol.Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodellingInterstitial myocardial fibrosis in a captive chimpanzee (Pan troglodytes) populationDevelopment of nonfibrotic left ventricular hypertrophy in an ANG II-induced chronic ovine hypertension model.Atrial natriuretic peptide suppresses endothelin gene expression and proliferation in cardiac fibroblasts through a GATA4-dependent mechanism.Protective effects of intercalated disk protein afadin on chronic pressure overload-induced myocardial damage.Cardiovascular effects of losartan and its relevant clinical application.Extracellular Superoxide Dismutase Expression in Papillary Thyroid Cancer Mesenchymal Stem/Stromal Cells Modulates Cancer Cell Growth and Migration.Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice.Adventitial fibroblasts in vascular structure and function: the role of oxidative stress and beyond.TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection.Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target.Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice.Inflammation in Heart Failure: known knowns and unknown unknowns.Modeling the Human Scarred Heart In Vitro: Toward New Tissue Engineered Models.Role of integrins in mediating cardiac fibroblast-cardiomyocyte cross talk: a dynamic relationship in cardiac biology and pathophysiology.Attenuation of monocyte chemotaxis--a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type natriuretic peptide.Mitogen-activated protein kinase p38 target regenerating islet-derived 3γ expression is upregulated in cardiac inflammatory response in the rat heart.Comparison of Left Ventricular Hypertrophy, Fibrosis and Dysfunction According to Various Disease Mechanisms such as Hypertension, Diabetes Mellitus and Chronic Renal Failure.Sang-qi Granula Reduces Blood Pressure and Myocardial Fibrosis by Suppressing Inflammatory Responses Associated with the Peroxisome Proliferator-Activated Receptors and Nuclear Factor κ B Protein in Spontaneously Hypertensive Rats.Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation.Simvastatin prevents large blood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras-ERK pathways.DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure.
P2860
Q27326691-9270968D-2076-4E23-851B-3F4EC892EC7BQ28075944-491A6E8D-7A25-43BB-8D58-B31C6B412123Q28582102-04108827-B321-402C-A923-FC1F48B95A84Q28654538-AA086082-2E29-4A72-AC9B-1CE88C6DABE3Q33402947-F5631023-BBDA-4DDA-AA41-4D42E113DAB6Q33428506-F85804DA-013A-47F7-B02F-BBF6BAC49CADQ33772867-420C055D-474A-48C5-8207-2D61925BB664Q33828715-A166A0F0-4C97-4E16-88C7-D15AD849D626Q34332023-1060A7B3-4423-40CC-85DD-9167FC633719Q35168394-97C2AEA2-E514-4E0F-91AE-155E8BD8B6F6Q35196311-E18541F6-8ECD-4958-86CC-A655B3489CEDQ35207988-AEE49BC5-CBA5-4EBF-BC6A-0C7D448B01E6Q35534909-456E3DF3-BC2B-436A-B1F1-2AF1D849E644Q36067020-A94401CD-A4B9-4A9F-A1A1-E581712A406BQ36514296-CA06E058-A544-4969-B7C8-14C118E96503Q37019326-748FD59B-39C0-41E6-BC29-C587FA6D0D67Q37056105-7C75E000-F07B-4CDC-83C4-00B79D430218Q37090971-5585B65A-7B5E-46E5-8733-2EE26CD02B36Q37096257-F34EDEAA-1B3D-421C-B51A-A63990EB9CA3Q37251259-5D401896-9A1D-4ED3-8250-DF2D6128CC27Q37263881-C02649B1-AE60-47DC-9175-BBD5A9CE8480Q37385629-A9DDB0D4-DEB3-4C9A-B074-C27CDD82FB7EQ37550499-B19102E1-196F-4765-96CE-C67A56DCEF36Q37595599-69CECA02-BDFB-442B-BD08-2F2573B4F9D3Q37652212-3EAFED21-FDC5-4D91-803F-0D4FDA9AE981Q37715790-2F4BA28F-2013-4DDC-A4ED-AD9764116E38Q37731327-10F9AA0E-DACE-43B3-9DE1-FAA6E4128364Q37773292-6132ABEB-E8F1-4CC0-85CC-8CF143AA3678Q38134311-9F5E7178-55D1-45AE-9C73-D6D89260E4FAQ38584976-F1A83ACA-F0F8-4642-BFC9-7843AEB78135Q38692564-F6123681-8D72-407D-ADB7-FC8525A38FAFQ38788603-E831D1FF-D05A-47E1-9F1D-B18D8C503ADCQ39045116-1B4ACA10-C661-4A8D-AA9B-2B1A32820915Q39159036-25CD64F6-17BC-4706-93E4-0AA4A963B1A5Q39231230-64211785-692E-4342-8A6E-B4663918F4D6Q41253251-8379048C-5230-4900-9E42-F76E8FBBC225Q42141141-E12AB79A-AAD1-4F86-8E77-81A0E4219CC9Q42273281-960C0B1B-D9E1-4739-A975-C8B9F0E0488AQ42788177-6CA92DF8-4EB9-44C8-BEF9-461AEB20697CQ43054868-9FF88A78-C7D0-44F3-969E-5C5522502A77
P2860
Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors.
@ast
Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors.
@en
type
label
Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors.
@ast
Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors.
@en
prefLabel
Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors.
@ast
Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors.
@en
P1476
Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors.
@en
P2093
Nicoletti A
P304
P356
10.1016/S0008-6363(98)00305-8
P577
1999-03-01T00:00:00Z